Emergent BioSolutions: More Than An Emerging Biotech

Bioterrorism threats and infectious disease outbreaks are on the rise. Emergent BioSolutions Inc. (EBS) has a stream of revenues from FDA-approved drugs, as well as a full pipeline of drugs under development, to combat these health threats.

Over 50% of the company’s 2017 revenues come from its BioThrax anthrax vaccinations. In addition to rising anthrax outbreaks in animals, biowarfare is a looming threat. North Korea has 13 bioweapons in stock, of which anthrax is the most likely to be used, says South Korea. EBS is rapidly expanding its product line beyond anthrax to address a range of biological, chemical and emerging disease risks.


READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.

Baltimore Business Spotlight

Feature Your Business Here

Connect with these Baltimore Professionals on LinkedIn

  • Edwin Warfield

    Editor in Chief, Warfield Digital

    Connect
  • Jean Halle

    Independent Consultant

    Connect
  • Larry Lichtenauer

    President of Lawrence Howard & Associates

    Connect
  • Newt Fowler

    Partner at Womble Carlyle, LLP

    Connect
  • David Crowley

    Owner at Develop DC

    Connect
  • Carolyn Stinson

    Stinson Marketing Group

    Connect